These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 6791010)

  • 1. Solid solutions as long-acting naltrexone delivery systems.
    Olsen JL
    NIDA Res Monogr; 1981; 28():265-71. PubMed ID: 6791010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained release of naltrexone from glyceride implants.
    Sullivan MF; Kalkward DR
    Natl Inst Drug Abuse Res Monogr Ser; 1975; (4):27-32. PubMed ID: 1234982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained release of naltrexone from glyceride implants.
    Sullivan MF; Kalkwarf DR
    Natl Inst Drug Abuse Res Monogr Ser; 1976 Jan; (4):27-32. PubMed ID: 967232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of parenteral sustained-release naltrexone systems.
    Olsen JL; Kincl FA
    NIDA Res Monogr; 1981; 28():187-93. PubMed ID: 6791004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma corticosteroid levels in rats maintained on a long-acting naltrexone delivery system.
    Misra AL; Pontani RB; Vadlamani NL
    Res Commun Chem Pathol Pharmacol; 1978 Apr; 20(1):43-50. PubMed ID: 663407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic quantitation of naltrexone release from several sustained-release delivery systems.
    Reuning RH; Liao SH; Staubus AE
    NIDA Res Monogr; 1981; 28():172-84. PubMed ID: 6791003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of synthetic polypeptides in the preparation of biodegradable delivery vehicles for narcotic antagonists.
    Sidman KR; Arnold DL; Steber WD; Nelsen L; Granchelli FE; Strong P; Sheth SG
    Natl Inst Drug Abuse Res Monogr Ser; 1975; (4):33-8. PubMed ID: 1234983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Chronomers for narcotic antagonists.
    Capozza RC; Schmitt EE; Sendelbeck LR
    Natl Inst Drug Abuse Res Monogr Ser; 1975; (4):39-42. PubMed ID: 13306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing of drug delivery systems for use in the treatment of narcotic addiction.
    Reuning RH; Malspeis L; Frank S; Notari RE
    Natl Inst Drug Abuse Res Monogr Ser; 1975; (4):43-5. PubMed ID: 827709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Historical perspective on the chemistry and development of naltrexone.
    Archer S
    NIDA Res Monogr; 1981; 28():3-10. PubMed ID: 6791011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Narcotic antagonists: naltrexone pharmacochemistry and sustained-release preparations.
    NIDA Res Monogr; 1981; 28():1-273. PubMed ID: 6790998
    [No Abstract]   [Full Text] [Related]  

  • 12. Characterization of a potential medium for 'biorelevant' in vitro release testing of a naltrexone implant, employing a validated stability-indicating HPLC method.
    Iyer SS; Barr WH; Karnes HT
    J Pharm Biomed Anal; 2007 Feb; 43(3):845-53. PubMed ID: 17045445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of polylactic/glycolic acid delivery systems for use in treatment of narcotic addiction.
    Schwope AD; Wise DL; Howes JF
    Natl Inst Drug Abuse Res Monogr Ser; 1976 Jan; (4):13-8. PubMed ID: 787798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 'biorelevant' approach to accelerated in vitro drug release testing of a biodegradable, naltrexone implant.
    Iyer SS; Barr WH; Karnes HT
    Int J Pharm; 2007 Aug; 340(1-2):119-25. PubMed ID: 17482777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of polylactic/glycolic acid delivery systems for use in treatment of narcotic addiction.
    Schwope AD; Wise DL; Howes JF
    Natl Inst Drug Abuse Res Monogr Ser; 1975; (4):13-8. PubMed ID: 1241970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of synthetic polypeptides in the preparation of biodegradable delivery vehicles for narcotic antagonists.
    Sidman KR; Arnold DL; Steber WD; Nelsen L; Granchelli FE; Strong P; Sheth SG
    Natl Inst Drug Abuse Res Monogr Ser; 1976 Jan; (4):33-8. PubMed ID: 967233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting injectable naltrexone for the treatment of alcohol dependence.
    Mannelli P; Peindl K; Masand PS; Patkar AA
    Expert Rev Neurother; 2007 Oct; 7(10):1265-77. PubMed ID: 17939765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles.
    Kranz H; Bodmeier R
    Eur J Pharm Sci; 2008 Jul; 34(2-3):164-72. PubMed ID: 18501569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and in vitro evaluation of mucoadhesive properties of alginate/chitosan microparticles containing prednisolone.
    Wittaya-areekul S; Kruenate J; Prahsarn C
    Int J Pharm; 2006 Apr; 312(1-2):113-8. PubMed ID: 16490331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 'biorelevant' system to investigate in vitro drug released from a naltrexone implant.
    Iyer SS; Barr WH; Dance ME; Coleman PR; Karnes HT
    Int J Pharm; 2007 Aug; 340(1-2):104-18. PubMed ID: 17482393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.